DA Davidson & CO. buys 11,986 shares of Johnson & Johnson (NYSE:JNJ)

DA Davidson & CO. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.1% during the second quarter, Holdings Channel.com reports. The firm owned 582,121 shares of the company’s stock after acquiring an additional 11,986 shares during the period. Johnson & Johnson comprises 0.8% of the DA Davidson & CO portfolio. DA Davidson & CO holdings. in Johnson & Johnson were worth $85,082,000 as of its most recent SEC filing.

Several other large investors have recently made changes to their positions in the business. Inçalta Capital LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at $27,000. Christopher J. Hasenberg Inc acquired a new position in shares of Johnson & Johnson in the first quarter valued at $31,000. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at $44,000. MFA Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at $43,000. Finally, Grayhawk Investment Strategies Inc. raised its stake in shares of Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after acquiring an additional 259 shares during the period. Institutional investors own 69.55% of the company’s shares.

Johnson & Johnson trading rose 1.0%

NYSE JNJ opened at $165.86 on Tuesday. The firm has a market cap of $399.17 billion, a P/E ratio of 10.34, a P/E/G ratio of 2.73 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07, and a quick ratio of 0.85. The stock’s 50-day moving average is $156.02 and its 200-day moving average is $153.53. Johnson & Johnson has a one year low of $143.13 and a one year high of $165.98.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s quarterly revenue was up 4.3% on a year-over-year basis. In the same period last year, the company earned $2.80 per share. sell-side analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson announces dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a dividend of $4.96 on an annualized basis and a dividend yield of 2.99%. Johnson & Johnson’s payout ratio is currently 30.92%.

Analysts on Wall Street are forecasting an increase

JNJ has been the subject of several research reports. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, August 5th. Morgan Stanley raised their price target on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. TD Cowen cut their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Finally, Goldman Sachs Group cut their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th . Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $173.21, according to MarketBeat.

See the latest stock analysis on JNJ

Johnson & Johnson Company Profile

(Free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Recommended articles

Want to see what other hedge funds JNJ owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Free Report).

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.